Incentives induce pharma expansion on Long Island; Mylan hands out EpiPens to schools;

@FiercePharma: Warning to Roche execs: Don't drink too much at a conference. Your peers are watching (and may report you). More | Follow @FiercePharma

@EricPFierce: Yet another pharmaceutical supplier makes a move on India to get in on the growing market there. News | Follow @EricPFierce

@AlisonBFierce: Rising vaccine prices mean fewer children are immunized. But competition from small vaccine makers could lower costs. Story | Follow @AlisonBFierce

> Incentives from Nassau County on Long Island persuaded PL Developments, an OTC drugmaker and packaging manufacturer, to expand in the area, adding 150 jobs. Report

> Mylan ($MYL) distributed EpiPens, which combat severe allergic reactions, to thousands of schools in the U.S. Report

> The Generic Pharmaceutical Association elected Tony Mauro, president of Mylan North America, to serve as board chairman for a second year. Release

> Aspen Pharmacare expects an increase in earnings per share for the first half of its fiscal year. Report

> Perrigo ($PRGO) was sued by an AbbVie ($ABBV) subsidiary and Besins Healthcare for patent infringement over the OTC drugmaker's plans to sell a version of the testosterone drug Androgel. Report

> Florida Gov. Rick Scott has done an about-face on expanding Medicaid in his state, in a move that could add 1.2 million patients to the state's rolls over 10 years. Report

Medical Device News

 @FierceMedDev: Report: Middle East, North Africa poised for major device and Dx growth. Item | Follow @FierceMedDev

 @MarkHFierce: Interesting challenge to the supremacy of surgical robots for a key procedure. News | Follow @MarkHFierce

 @DamianFierce: Allergan won FDA approval for its new breast implant, but the agency wants quite a bit of post-market data. Story | Follow @DamianFierce

> Boston Scientific reaches into Japan with spinal deal. Article

> Cheap blood test measures Hodgkin lymphoma chemo success. More

Biotech News

 @FierceBiotech: Ambit joins biotech IPO queue, seeks $58M as AML drug nears PhIII. News | Follow @FierceBiotech

@JohnCFierce: Manhandled by FDA in 2011, now a "no" in Europe. Gentium shares wrecked by fresh round of regulatory woes for lead drug. More | Follow @JohnCFierce

> Buzz: Shire's new CEO sends mixed signals on 'transformational' M&A strategy. Story

> Investors bankroll unique brains-and-beauty collaboration with $30M round. Article

Pharma Manufacturing News

> Drug shortages play role in growth at West Pharmaceutical. Story

> Mylan closes on oncology API plant as it rolls through India. Report

> China mandates track and trace while U.S. dithers. Article

> Dutch excipient player makes move on India. More

Vaccines News

> Rising vaccine prices mean fewer children immunized. News

> Indian court: Sanofi doesn't owe taxes on Shantha merger. Report

> Universal flu vaccine still 5 to 10 years away. Item

> HealthMap helps patients locate nearby vaccination sites. Article

> Australia begins vaccinating boys for HPV. Story

And Finally... The robot will see you now. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.